Dynavax (NASDAQ: DVAX) shares were trading 6.5% lower as of 3:35 p.m. EDT on Wednesday after competitor Pfizer (NYSE: PFE) reported data showing its vaccine produces a significantly larger number of antibodies than are found in recovered COVID-19 patients.
Dynavax is collaborating with a number of companies on the development of a COVID-19 vaccine, but trials involving the adjuvant it's contributing to boost immune responses in these collaborations have only just begun, suggesting other players, including Pfizer, may reach the market sooner.
Image source: Getty Images.